Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

M3GAN 2.0 takes that tradition to terrifying new extremes, particularly thanks to the unforgettable presence of Amelia. As ...

In “Sick and Dirty,” author Michael Koresky takes a clear-eyed look at golden age Hollywood’s stealth queerness on screen.

Justin Tucker, one of the best kickers in NFL history, suspended for 10 weeks after 16 women said he was sexually ...

The Democrat will be the first woman and one of fewer than 20 Minnesotans accorded the honor. She will lie in state with her ...

GAINESVILLE, Fla. (WCJB) - Florida Congresswoman Kat Cammack’s Gainesville and Ocala offices remain temporarily closed ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...